Speaker illustration

Professor Martin Landray

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

Martin Landray is Professor of Medicine & Epidemiology at the Nuffield Department of Population Health, University of Oxford, UK. He is Interim Director of the Big Data Institute & leads the clinical trials programme for Health Data Research UK. His research focuses on the use of digital technology and quality-by-design principles for large randomized trials of treatments for cardiovascular, including the SHARP, THRIVE, REVEAL, & ORION-4. He is co-chief investigator of the RECOVERY trial, which has enrolled 40,000 hospitalised patients with COVID-19. The trial identified that dexamethasone and tocilizumab reduce mortality but that many widely used treatments, including hydroxychloroquine and convalescent plasma have no meaningful impact on patient survival. He is a member of the European Society of Cardiology Regulatory Affairs Committee & leads the Good Clinical Trials Collaborative supported by Wellcome, Gates Foundation, and African Academy of Science.

Hot Line Session 5

Event: ESC CONGRESS 2019

Topic: European Society of Cardiology, Other

Session type: Late-Breaking Science


This platform is supported by

logo Novo Nordisk